CA2590906C - Deacylation of lps in gram negative bacteria - Google Patents

Deacylation of lps in gram negative bacteria Download PDF

Info

Publication number
CA2590906C
CA2590906C CA2590906A CA2590906A CA2590906C CA 2590906 C CA2590906 C CA 2590906C CA 2590906 A CA2590906 A CA 2590906A CA 2590906 A CA2590906 A CA 2590906A CA 2590906 C CA2590906 C CA 2590906C
Authority
CA
Canada
Prior art keywords
lps
pagl
lipid
bordetella
bacterium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2590906A
Other languages
English (en)
French (fr)
Other versions
CA2590906A1 (en
Inventor
Johannes Petrus Maria Tommassen
Peter Andre Van Der Ley
Jeroen Johannes Gerardus Geurtsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlanden Staat
Original Assignee
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlanden Staat filed Critical Nederlanden Staat
Publication of CA2590906A1 publication Critical patent/CA2590906A1/en
Application granted granted Critical
Publication of CA2590906C publication Critical patent/CA2590906C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2590906A 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria Expired - Fee Related CA2590906C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078445.6 2004-12-17
EP04078445 2004-12-17
PCT/NL2005/050081 WO2006065139A2 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Publications (2)

Publication Number Publication Date
CA2590906A1 CA2590906A1 (en) 2006-06-22
CA2590906C true CA2590906C (en) 2017-01-03

Family

ID=34928754

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2590906A Expired - Fee Related CA2590906C (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Country Status (15)

Country Link
US (1) US8048433B2 (enExample)
EP (1) EP1828378B1 (enExample)
JP (1) JP5378685B2 (enExample)
CN (1) CN101203605B (enExample)
AU (1) AU2005317304B2 (enExample)
BR (1) BRPI0519923A8 (enExample)
CA (1) CA2590906C (enExample)
DK (1) DK1828378T3 (enExample)
ES (1) ES2493440T3 (enExample)
MX (1) MX2007007288A (enExample)
NO (1) NO340331B1 (enExample)
NZ (1) NZ555889A (enExample)
PL (1) PL1828378T3 (enExample)
PT (1) PT1828378E (enExample)
WO (1) WO2006065139A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2134743E (pt) * 2007-03-26 2012-12-21 Nederlanden Staat Vacinas melhoradas contra bordotella pertussis baseadas nos mutantes do lps glicosiltransferase
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EA031879B1 (ru) 2013-06-04 2019-03-29 Пётр Геннадиевич Апарин Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CN104388368B (zh) * 2014-10-30 2017-02-15 四川农业大学 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法
WO2017129752A1 (en) * 2016-01-28 2017-08-03 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Modified tetra-acylated neisserial lps
CN105567620B (zh) * 2016-01-29 2019-03-19 江南大学 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用
CN105695540A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种革兰氏阴性菌胞壁抗原的制备方法
CN110461865A (zh) * 2017-03-13 2019-11-15 由卫生福利和体育大臣代表的荷兰王国 包含具有降低的反应原性的lps的博德特氏菌疫苗
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
US20230183656A1 (en) * 2020-05-14 2023-06-15 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
WO2022049222A1 (en) 2020-09-04 2022-03-10 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650681A5 (en) * 1981-08-14 1985-08-15 Dso Pharmachim Whooping cough vaccine
JP2918895B2 (ja) * 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE263244T1 (de) * 1992-08-18 2004-04-15 Dimminaco Ag Bordetella bronchiseptica impfstoff
CA2220048C (en) * 1995-05-04 2006-03-07 Connaught Laboratories Limited Acellular pertussis vaccines and methods of preparation thereof
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
ATE278419T1 (de) * 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6482807B1 (en) * 1998-11-03 2002-11-19 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation

Also Published As

Publication number Publication date
JP5378685B2 (ja) 2013-12-25
NO340331B1 (no) 2017-04-03
NO20073088L (no) 2007-09-17
BRPI0519923A2 (pt) 2009-08-11
WO2006065139A3 (en) 2006-10-19
US8048433B2 (en) 2011-11-01
DK1828378T3 (da) 2014-09-01
JP2008523805A (ja) 2008-07-10
EP1828378B1 (en) 2014-06-11
CN101203605B (zh) 2016-01-27
PL1828378T3 (pl) 2014-10-31
CA2590906A1 (en) 2006-06-22
NZ555889A (en) 2009-07-31
MX2007007288A (es) 2008-02-25
ES2493440T3 (es) 2014-09-11
BRPI0519923A8 (pt) 2018-01-23
AU2005317304B2 (en) 2011-06-23
PT1828378E (pt) 2014-10-10
CN101203605A (zh) 2008-06-18
EP1828378A2 (en) 2007-09-05
AU2005317304A1 (en) 2006-06-22
US20080274145A1 (en) 2008-11-06
WO2006065139A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
CA2590906C (en) Deacylation of lps in gram negative bacteria
Geurtsen et al. Dissemination of lipid A deacylases (pagL) among gram-negative bacteria: identification of active-site histidine and serine residues
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
CN105120892B (zh) 包含艰难梭菌cdtb和/或cdta蛋白的元件的免疫原性组合物
JPH10513349A (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
JP2020510726A (ja) 低下した反応源性を有するｌｐｓを含むボルデテラワクチン
EP4419135A1 (en) Lipopolysaccharide (lps) deficient acinetobacter baumannii multivalent vaccine
US10414805B2 (en) Gonorrheal MtrE peptides and vaccines
US20200317759A1 (en) Immunogenic compositions comprising staphylococcus aureus leukocidin luka and lukb derived polypeptides
Leão et al. A species-specific nucleotide sequence of Mycobacterium tuberculosis encodes a protein that exhibits hemolytic activity when expressed in Escherichia coli
Lo et al. Characterization of two lipoproteins in Pasteurella multocida
AU2017346974B2 (en) Vaccine constructs and uses thereof against staphylococcus infections
West et al. Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis
CN106536544B (zh) 艰难梭菌免疫原性组合物
CA2378862C (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
Jurado-Martín et al. Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ
JP7303791B2 (ja) スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
RU2677790C1 (ru) Рекомбинантная плазмидная ДНК pPA-OPRF-ATOX-OPRI, кодирующая синтез гибридного рекомбинантного белка, включающего аминокислотные последовательности белков F и I наружной мембраны и атоксического варианта экзотоксина A Pseudomonas aeruginosa, штамм Escherichia coli PA-OPRF-ATOX-OPRI - продуцент гибридного рекомбинантного белка и способ получения указанного белка
Jang et al. Comparative structural and immunological analysis of outer membrane proteins and dermonecrotic toxin in Bordetella bronchiseptica canine isolate
Geurtsen Improving pertussis vaccines by lipopolysaccharide engineering
Traidej Virulence and molecular analysis of Pseudomonas protease IV, a lysine-specific endopeptidase
Tidhar et al. The NlpD Lipoprotein Is a Novel Yersinia pestis Virulence Factor Essential for the
HK1189912B (en) Means of controlling infection persistence of helicobacter pylori

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20211216